Current Report Filing (8-k)
October 06 2020 - 6:09AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 6, 2020
PROPHASE
LABS, INC.
(Exact
name of Company as specified in its charter)
Delaware
|
|
000-21617
|
|
23-2577138
|
(State
or other
jurisdiction
of incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
621
N. Shady Retreat Road
Doylestown,
PA
|
|
18901
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Company’s
telephone number, including area code: (215) 345-0919
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under
any of the following provisions (see General Instruction A.2. below):
|
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
Registered Pursuant to Section 12(b) of the Exchange Act:
|
Title
of Each Class
|
|
Trading
Symbol
|
|
Name
of Each Exchange on Which
Registered
|
Common
Stock, par value $0.0005
|
|
PRPH
|
|
Nasdaq
Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
7.01 Regulation FD Disclosure
On October 6, 2020,
ProPhase Labs, Inc. (the “Company”) updated its investor presentation. A copy of the presentation is attached
to this Current Report as Exhibit 99.1 and will be posted on the Company’s website, which is located at www.prophaselabs.com.
The
information in this Item 7.01 and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any registration statement filed under the Securities
Act of 1933, as amended, unless specifically identified therein as being incorporated by reference therein.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
ProPhase
Labs, Inc.
|
|
|
|
|
By:
|
/s/
Monica
Brady
|
|
|
Monica
Brady
|
|
|
Chief
Financial Officer
|
Date:
October 6, 2020
ProPhase Labs (NASDAQ:PRPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
ProPhase Labs (NASDAQ:PRPH)
Historical Stock Chart
From Apr 2023 to Apr 2024